Page last updated: 2024-10-30

mesalamine and Hamartoma Syndrome, Multiple

mesalamine has been researched along with Hamartoma Syndrome, Multiple in 1 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Hamartoma Syndrome, Multiple: A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Galatola, M1
Miele, E1
Strisciuglio, C1
Paparo, L1
Rega, D1
Delrio, P1
Duraturo, F1
Martinelli, M1
Rossi, GB1
Staiano, A1
Izzo, P1
De Rosa, M1

Other Studies

1 other study available for mesalamine and Hamartoma Syndrome, Multiple

ArticleYear
Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis.
    World journal of gastroenterology, 2013, Dec-14, Volume: 19, Issue:46

    Topics: Adenomatous Polyposis Coli; Age of Onset; Anti-Infective Agents; Azathioprine; beta Catenin; Biomark

2013